Modern synthetic biology and AI represent both medicine’s greatest breakthrough and warfare’s most terrifying evolution. In this new landscape, where biological weapons can be designed faster than ...

In a small clinical trial, customized mRNA vaccines against high-risk skin cancers appeared to reduce the risk of cancer recurrence and death by nearly 50 percent over five years when compared with ...

Stanford scientists have uncovered how mRNA COVID-19 vaccines can very rarely trigger heart inflammation in young men — and how that risk might be reduced. They found that the vaccines can spark a two ...

The recent downturn follows Moderna’s announcement that its melanoma vaccine, mRNA-4157, showed promising results in a Phase 2b study, reducing the risk of recurrence or death by 49% when combined ...

A new vaccine that boosts immunity against tuberculosis (TB) has been shown to be effective in pioneering pre-clinical trials. A new vaccine that boosts immunity against tuberculosis (TB) has been ...

Moderna's stock, down 91% from its peak, jumped 16% on positive Phase 2b results for its mRNA skin cancer vaccine, showing a 49% reduction in recurrence. This cancer vaccine is vital for Moderna to ...

Jan 20 (Reuters) - Moderna (MRNA.O), opens new tab and Merck (MRK.N), opens new tab said on Tuesday their experimental personalized vaccine continued to cut the risk of death or recurrence of the most ...

Adding Merck & Co. and Moderna’s vaccine candidate to Keytruda has continued to cut the risk of cancer recurrence or death across five years of follow-up, boosting the companies’ prospects as they ...

You're currently following this author! Want to unfollow? Unsubscribe via the link in your email. Follow Brent D. Griffiths Every time Brent D. Griffiths publishes a story, you’ll get an alert ...

Since Nvidia agreed last month to invest $100 billion in its customer OpenAI, investors and analysts who follow artificial intelligence have awakened to that industry’s circularity.